復星醫藥(600196.SH)控股子公司藥品HLX316獲臨床試驗批准

智通財經

03/09

智通財經APP訊，復星醫藥(600196.SH)發布公告，近日，公司控股子公司上海復宏漢霖生物技術股份有限公司及其控股子公司(合稱「復宏漢霖」)收到國家藥品監督管理局關於同意注射用HLX316(即靶向B7-H3的唾液酸酶Fc融合蛋白，簡稱「HLX316」)用於晚期/轉移性實體瘤治療開展Ⅰ期臨床試驗的批准。復宏漢霖擬於條件具備後在中國境內1開展該藥品的相關臨床研究。

HLX316系集團利用靶向B7-H3的僅含重鏈的抗體可變區(VHH)與許可引進的唾液酸酶雙功能融合蛋白融合開發的唾液酸酶Fc融合蛋白，為一種新型、首創、靶向B7-H3的唾液酸酶異源二聚體，擬用於晚期/轉移性實體瘤治療。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2618444106"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618444106\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618444106?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-09 17:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618444106","market":"fut","top_or_hot":-1,"title":"復星醫藥(600196.SH)控股子公司藥品HLX316獲臨床試驗批准","media":"智通財經","content":"<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/600196\">復星醫藥</a>(600196.SH)發布公告，近日，公司控股子公司上海<a href=\"https://laohu8.com/S/02696\">復宏漢霖</a>生物技術股份有限公司及其控股子公司(合稱「復宏漢霖」)收到國家藥品監督管理局關於同意注射用HLX316(即靶向B7-H3的唾液酸酶Fc融合蛋白，簡稱「HLX316」)用於晚期/轉移性實體瘤治療開展Ⅰ期臨床試驗的批准。復宏漢霖擬於條件具備後在中國境內1開展該藥品的相關臨床研究。</p><p>HLX316系集團利用靶向B7-H3的僅含重鏈的抗體可變區(VHH)與許可引進的唾液酸酶雙功能融合蛋白融合開發的唾液酸酶Fc融合蛋白，為一種新型、首創、靶向B7-H3的唾液酸酶異源二聚體，擬用於晚期/轉移性實體瘤治療。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>復星醫藥(600196.SH)控股子公司藥品HLX316獲臨床試驗批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n復星醫藥(600196.SH)控股子公司藥品HLX316獲臨床試驗批准\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-03-09 17:47</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/600196\">復星醫藥</a>(600196.SH)發布公告，近日，公司控股子公司上海<a href=\"https://laohu8.com/S/02696\">復宏漢霖</a>生物技術股份有限公司及其控股子公司(合稱「復宏漢霖」)收到國家藥品監督管理局關於同意注射用HLX316(即靶向B7-H3的唾液酸酶Fc融合蛋白，簡稱「HLX316」)用於晚期/轉移性實體瘤治療開展Ⅰ期臨床試驗的批准。復宏漢霖擬於條件具備後在中國境內1開展該藥品的相關臨床研究。</p><p>HLX316系集團利用靶向B7-H3的僅含重鏈的抗體可變區(VHH)與許可引進的唾液酸酶雙功能融合蛋白融合開發的唾液酸酶Fc融合蛋白，為一種新型、首創、靶向B7-H3的唾液酸酶異源二聚體，擬用於晚期/轉移性實體瘤治療。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1411678.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"醫美概念股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1411678.html","article_id":"2618444106","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618444106","pubTimestamp":1773049650,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP訊，復星醫藥(600196.SH)發布公告，近日，公司控股子公司上海復宏漢霖生物技術股份有限公司及其控股子公司(合稱「復宏漢霖」)收到國家藥品監督管理局關於同意注射用HLX316(即靶向B7-H3的唾液酸酶Fc融合蛋白，簡稱「HLX316」)用於晚期/轉移性實體瘤治療開展Ⅰ期臨床試驗的批准。復宏漢霖擬於條件具備後在中國境內1開展該藥品的相關臨床研究。HLX316系集團利用靶向B7-H3的僅含重鏈的抗體可變區(VHH)與許可引進的唾液酸酶雙功能融合蛋白融合開發的唾液酸酶Fc融合蛋白，為一種新型、首創、靶向B7-H3的唾液酸酶異源二聚體，擬用於晚期/轉移性實體瘤治療。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK1593":"医美概念股","BK0012":"证金概念","02196":"复星医药","BK0175":"白马股","BK0196":"行业龙头","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队","BK0239":"医药制造","BK0096":"民营医院","BK1515":"抗疫概念","BK0183":"MSCI概念","BK0188":"融资融券","BK1191":"制药"},"translate_title":"Fosun Pharma (600196.SH) holding subsidiary drug HLX316 obtained clinical trial approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"智通財經APP訊，復星醫藥(600196.SH)發布公告，近日，公司控股子公司上海復宏漢霖生物技術股份有限公司及其控股子公司(合稱「復宏漢霖」)收到國家藥品監督管理局關於同意注射用HLX316(即靶向B7-H3的唾液酸酶Fc融合蛋白，簡稱「HLX316」)用於晚期/轉移性實體瘤治療開展Ⅰ期臨床試驗的批准。復宏漢霖擬於條件具備後在中國境內1開展該藥品的相關臨床研究。HLX316系集團利用靶向B7-H3的僅含重鏈的抗體可變區(VHH)與許可引進的唾液酸酶雙功能融合蛋白融合開發的唾液酸酶Fc融合蛋白，為一種新型、首創、靶向B7-H3的唾液酸酶異源二聚體，擬用於晚期/轉移性實體瘤治療。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}